SLU-PP-332 1000mcg Capsules

KEY SPECIFICATIONS

PRODUCT OVERVIEW

SLU-PP-332 is a selective pan-ERR agonist that functions as an exercise-mimetic research compound by activating metabolic pathways typically stimulated by physical training. This synthetic hydrazide derivative modulates the ERRα-PGC-1α axis, enabling investigation of mitochondrial biogenesis, fatty acid oxidation, and muscle fiber type transformation without exercise variables.

Preclinical research demonstrates 70% longer running endurance and 12% body weight reduction in metabolic models. BIONIX supplies laboratory-grade SLU-PP-332 with ≥99% purity and batch-specific COA.

MECHANISM OF ACTION

SLU-PP-332 activates the Estrogen-Related Receptor family (ERRα, ERRβ, ERRγ)—orphan nuclear receptors that function as master regulators of energy metabolism. Unlike estrogen receptors, ERRs do not bind estrogen but regulate genes essential for oxidative phosphorylation and mitochondrial function.

Primary Pathway:

The ERRα-PGC-1α Axis: SLU-PP-332 stabilizes ERRα interaction with PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional co-activator of mitochondrial biogenesis. This recruitment activates gene programs for:

• Mitochondrial DNA replication and membrane formation
• Electron transport chain assembly
• Fatty acid oxidation enzyme expression
• Type IIa oxidative muscle fiber promotion

The Exercise-Mimetic Effect: By activating ERRα-mediated transcription, SLU-PP-332 triggers the same genetic adaptations normally requiring weeks of endurance training—enhanced oxidative capacity, increased mitochondrial density, and improved metabolic flexibility—without physical exercise protocols.

Comparative Profile:

RESEARCH APPLICATIONS

Mitochondrial Biogenesis Research: Investigation of cellular mechanisms for forming new mitochondria and increasing oxidative capacity. SLU-PP-332 serves as a chemical probe for activating the PGC-1α/ERRα complex, enabling controlled study of organelle biogenesis without exercise confounders.

Exercise-Mimetics Research: Analysis of endurance adaptation mechanisms through ERR pathway activation. Preclinical studies (2023-2024) demonstrate 70% longer treadmill running time and 45% greater distance capacity without increased physical activity—providing a tool to isolate metabolic adaptations from mechanical training effects.

Lipid Metabolism Studies: Examination of fatty acid oxidation and substrate switching in skeletal muscle. SLU-PP-332 enables investigation of metabolic flexibility, β-oxidation pathway kinetics, and lipid droplet mobilization mechanisms in controlled experimental conditions.

Metabolic Syndrome Models: Research on insulin sensitivity, adiposity resistance, and energy expenditure. Mouse studies demonstrate 12% body weight reduction in obese models alongside improved metabolic markers—supporting obesity and metabolic disease mechanism investigations.

Muscle Fiber Type Analysis: Investigation of oxidative fiber transformation. SLU-PP-332 promotes Type IIa oxidative fiber characteristics and increased mitochondrial density, enabling research on muscle plasticity and endurance phenotype development.

ANALYTICAL VERIFICATION

BIONIX SLU-PP-332 undergoes comprehensive analytical characterization:

• HPLC Analysis: ≥99% purity confirmation via optimized chromatographic separation
• Mass Spectrometry: Identity verification and molecular weight confirmation (290.32 g/mol)
• Stability Testing: Shelf-life validation under specified storage conditions

Physical Characteristics:

DEVELOPMENT STATUS

SLU-PP-332 remains in preclinical development:

• Preclinical Stage: Animal studies completed, human trials pending
• Regulatory Status: Not FDA or EMA approved
• WADA Classification: Prohibited substance (S4.5 Metabolic Modulators)
• Research Applications: Metabolic research, mitochondrial studies, exercise mimetics

SLU-PP-332 is intended exclusively for laboratory research purposes.

FREQUENTLY ENCOUNTERED INQUIRIES

What is the ERR mechanism and how does SLU-PP-332 function?
SLU-PP-332 activates Estrogen-Related Receptors (ERRα, ERRβ, ERRγ)—nuclear receptors regulating metabolic gene expression. By stabilizing ERRα interaction with PGC-1α, it activates transcription of genes for mitochondrial biogenesis and oxidative metabolism, mimicking exercise adaptations without physical training.

How does SLU-PP-332 differ from GW501516 (Cardarine)?
SLU-PP-332 targets ERR receptors while GW501516 activates PPARδ. Both induce metabolic effects but through distinct signaling pathways—SLU-PP-332 emphasizes mitochondrial biogenesis via ERR-PGC-1α, whereas GW501516 focuses on PPARδ-mediated fatty acid oxidation.

What were the key preclinical findings?
Mouse studies demonstrated 70% longer running time, 45% greater distance, and 12% body weight reduction in obese models—all without increased physical activity. Muscle analysis revealed increased Type IIa oxidative fiber content and enhanced mitochondrial markers.

What are the primary research applications?
Mitochondrial biogenesis research, exercise-mimetic pathway investigation, lipid metabolism analysis, metabolic syndrome models, and muscle fiber type transformation studies. All applications limited to controlled laboratory environments.

What storage conditions are required?
Store capsules at -20°C for long-term stability. Avoid repeated freeze-thaw cycles and protect from light and moisture.

Is SLU-PP-332 approved for human use?
Negative. SLU-PP-332 is intended exclusively for laboratory research. No human clinical trials have been completed. Not FDA or EMA approved.

References

1. Narkar VA et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell, 2008;134(3):405-415. PMID: 18674809
2. Fan W et al., “PPARδ promotes running endurance by preserving glucose,” J Biol Chem, 2004;279(7):5241-5248. PMID: 14638679
3. Billon C et al., “The ERR family of nuclear receptors: from metabolism to cancer,” Cell Metab, 2022;34(1):69-84. PMID: 34756173